返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® and MicroPort® Endovascular Attend CHC 2017

[2017-09-12] 

Beijing, China – From August 10 to August 13, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") and MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the 2017 China Heart Congress ("CHC 2017") & the Second China Vascular Congress ("CVC") held in China National Convention Center of Beijing and hosted a satellite meeting. The congress was hosted by Chinese Medical Association and National Center for Cardiovascular Disease and was themed "Healthy Heart • Better Life: Innovation, Translation, and Cooperation."
 
On August 11, MicroPort® hosted a satellite meeting on the latest update of TARGET Serial Clinical Trials of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"). The meeting was co-chaired by Professor Shubin Qiao of Fuwai Hospital of Chinese Academy of Medical Sciences, Professor Juying Qian of Zhongshan Hospital, Professor Yan Li of Xijing Hospital of the Fourth Military University, and Professor Yuming Lu of the First People's Hospital of Guiyang. Professor Lijian Gao of Fuwai Hospital of Chinese Academy of Medical Sciences, Professor Hongyu Shi of Shanghai Chest Hospital, and Professor Binchen Liu of the Fourth Affiliated Hospital of Harbin Medical University were invited to analyze typical cases for the attendees. In the end of the satellite meeting, Professor Bo Xu of Fuwai Hospital of Chinese Academy of Medical Sciences announced the three-month Optical Computerized Tomography ("OCT") data from the TARGET All Comer trial, which demonstrated early vessel healing with Firehawk® and showed non-inferiority results compared to Xience family stents. Experts in attendance spoke highly of Firehawk®'s safety and efficacy proved in clinical studies.
 
In the CHC 2017, MicroPort® displayed coronary stents and balloons and set up the VR experience center in MicroPort® booth, which attracted wide attention from attendees. Professor Bo Xu and Kefei Dou of Fuwai Hospital of Chinese Academy of Medical Sciences also visited MicroPort® booth and its VR experience center. They said, in the VR experience center of MicroPort®, the visitor can experience the whole PCI procedure taking place in the coronary artery lesion from the perspective of the guide wire or stent, which provided visitors a more vivid understanding in the innovative features of Firehawk®. They highly recognized such innovative display and said it was worth popularizing.
 
During the CHC 2017, MicroPort® Endovascular hosted a satellite meeting on "Treatment Strategies of Aortic Arch Lesion." The meeting was co-chaired by Professor Chang Shu of Fuwai Hospital of Chinese Academy of Medical Sciences, Professor Yuqiang Shang of the Central Hospital of Wuhan, and Professor Peiyong Hou of Liuzhou Worker's Hospital. Professor Kun Fang of Fuwai Hospital of Chinese Academy of Medical Sciences, Professor Wei Li of People's Hospital of Peking University , and Professor Shangdong Xu of Beijing Anzhen Hospital of Capital Medical University were invited as keynote speakers to discuss about the treatment strategies of aortic arch in terms of endovascular treatment and surgical treatment. During the meeting, the experts mentioned the "soft sheath cross arch" design of Hercules® Low Profile Cross Thoracic Stent-Graft ("Hercules® Low Profile"), Castor® Branched Aortic Stent-Graft System ("Castor®"), and Fontus® Single-branched Stent Graft System in Surgical Operation. The three products in-house developed by MicroPort® Endovascular are all indicated for aortic arch. Hercules® Low Profile adopts the arch with a soft sheath. The stent graft is delivered and deployed under the protection of the soft sheath, which improves the traceability across the arch as well as the stability during deployment due to less stress incurred by the soft sheath when crossing the arch. Castor® adopts unibody design with no gap between the main body and the branch to avoid gutter endoleak commonly occurred in chimney technique and type III endoleak commonly seen in fenestrated technique, as well as to eliminate the risk of long-term migration of the modular stent-graft, so as to ensure the long-term stability. The design of dual access introducing and delivery system of Castor® that works with its unibody design will guarantee precise and stable deployment. Compared to CRONUS® Surgical Stent Graft System ("CRONUS®"), the new-generation Fontus® Single-branched Stent Graft System in Surgical Operation has several added advantages: Left subclavian artery ("LSA") can be reconstructed directly by the newly added single branch, which shortens the time of LSA suture and makes the operation less difficult. The newly added coating on the proximal artificial blood vessel can significantly alleviate the suture bleeding. The device offers different lengths of the proximal artificial blood vessel, and physicians can choose different suture methods according to the involvement degree of dissection, such as island and etc. The stent is made of NiTi memory alloy and the stent sections are independent of each other. Besides, its flexibility was significantly improved compared to CRONUS®.
 
The CHC 2017 displayed new achievements in clinical prevention and basic research of cardiovascular diseases, aortic diseases, peripheral vessel diseases and other related diseases, introduced new developments in translational medical research, explored the future trend of integrated medicine and individualized treatment, prevention and research, so as to further promote the development of cardiology in China. MicroPort® is dedicated to providing patients with safe, effective and affordable cardiac interventional solutions through constant innovation and by integrating cutting-edge techniques and scientific achievements in various fields.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:First Domestically Made World-Class Pacemaker Device Gains CFDA Approval
[Next]:Firefighter™ PTCA Balloon Catheter Receives Regulatory Approval in South Korea